RxDoctor Payments DataLook up a doctor →

Gregory Andros, MD

Urology · Joliet, ILNPI 1962481143

Payments from drug & device makers

$329,624in general payments, 2019–2025

Across 623 payments — averaging $529.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dendreon Pharmaceuticals LLC$118K
  • Janssen Research & Development, LLC$98K
  • Sumitomo Pharma America, Inc.$92K
  • Neotract Inc.$5K
  • Teleflex LLC$2K
  • Bayer$2K
  • plus $12K from 54 others
$3,500in research payments, 2019–2025

Across 1 payment — averaging $3500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Dendreon Pharmaceuticals LLC$4K

What the payments were for

  • Consulting fees$1,8808%
  • Speaking & faculty fees$5,03122%
  • Travel & lodging$1,6137%
  • Food & beverage$13,29358%
  • Education$9104%
  • Other$630%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Dendreon Pharmaceuticals LLC40$117,901
Janssen Research & Development, LLC13$97,968
Sumitomo Pharma America, Inc.50$91,592
Neotract Inc.25$5,452
Teleflex LLC17$2,427
Bayer18$2,284
Astellas Pharma US Inc46$1,538
Coloplast51$1,428
Pfizer12$1,133
Olympus America Inc.34$1,027
Boston Scientific22$698
Antares Pharma, Inc.89$624
Axonics, Inc.19$569
Laborie Medical Technologies Corp.9$494
AbbVie(2 entities)16$460
Johnson & Johnson(2 entities)14$324
Verity Pharmaceuticals Inc.16$279
Endo Pharmaceuticals Inc.14$271
Bioprotect Medical, Inc.4$248
Medtronic(2 entities)13$226
Myovant Sciences Inc.8$218
Procept Biorobotics Corporation3$197
Merck9$186
Valencia Technologies Corporation2$162
Endo USA, Inc.9$147
Calyxo, Inc.2$138
Ferring Pharmaceuticals Inc.5$130
Palette Life Sciences, Inc.2$128
AstraZeneca5$110
Amgen1$106
Progenics Pharmaceuticals, Inc.4$94
Telix Pharmaceuticals3$87
Rochester Medical Corporation4$84
Accord Healthcare, Inc.4$77
Myriad Genetic Laboratories, Inc.3$74
Tolmar, Inc.4$69
Baxter Healthcare1$63
Immunitybio, Inc.3$53
Novartis2$44
Sanofi2$43
Halozyme Inc2$43
Blue Earth Diagnostics2$39
Healthtronics Stone Solutions, LLC1$32
Convatec Inc.1$30
180 Medical, Inc.1$29
Bluewind Medical1$29
Profound Medical Corp.1$29
Urovant Sciences Inc2$28
Mission Pharmacal Company2$27
Siemens Medical Solutions USA, Inc.1$26
Urogen Pharma, Inc.1$24
Tolmar Pharmaceuticals, Inc.1$21
Travere Therapeutics, Inc.2$18
Cook Medical LLC1$18
Avadel Specialty Pharmaceuticals, LLC1$15
Vertex1$14
Lantheus Medical Imaging, Inc.1$14
Dentsply IH Inc.1$13
Hollister Incorporated1$13
Cardinal Health 414 LLC1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$329,624 in reported general payments places this provider in the 95th percentile of 550 urology providers in Illinois.

See all urology providers in Illinois

Medicare billing

Part B allowed, 2024
$758,851
Medicare patients
1,272
Services billed
34,510

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron113$77,286
MyrbetriqMirabegron68$60,305
Abiraterone Acetate16$10,716
Tamsulosin Hcl660$8,372
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst191$7,946
NitrofurantoinNitrofurantoin Macrocrystal74$3,058
Oxybutynin Chloride ErOxybutynin Chloride117$3,032
Finasteride210$2,607
Estradiol24$2,064
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim390$1,947
Potassium Citrate ErPotassium Citrate21$1,201
Tolterodine Tartrate ErTolterodine Tartrate27$766
Desmopressin Acetate12$765
Solifenacin Succinate40$495
Oxybutynin Chloride32$435

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$91,592$77,286113 claims
Astellas Pharma US IncMyrbetriq$1,538$60,30568 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 550 urology providers in Illinois.

Other urology in Joliet

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →